Your browser doesn't support javascript.
loading
BEX1 mediates sorafenib resistance in hepatocellular carcinoma by regulating AKT signaling.
Zhuang, Na; Gu, Zhiyun; Feng, Juan; Chai, Zixuan; Shan, Juanjuan; Qian, Cheng.
Afiliación
  • Zhuang N; Research Center for Precision Medicine, Chongqing Key Laboratory of Translational Research for Cancer Metastasis and Individualized Treatment, Chongqing University Cancer Hospital, Chongqing, China.
  • Gu Z; Research Center for Precision Medicine, Chongqing Key Laboratory of Translational Research for Cancer Metastasis and Individualized Treatment, Chongqing University Cancer Hospital, Chongqing, China.
  • Feng J; Research Center for Precision Medicine, Chongqing Key Laboratory of Translational Research for Cancer Metastasis and Individualized Treatment, Chongqing University Cancer Hospital, Chongqing, China.
  • Chai Z; Research Center for Precision Medicine, Chongqing Key Laboratory of Translational Research for Cancer Metastasis and Individualized Treatment, Chongqing University Cancer Hospital, Chongqing, China.
  • Shan J; Research Center for Precision Medicine, Chongqing Key Laboratory of Translational Research for Cancer Metastasis and Individualized Treatment, Chongqing University Cancer Hospital, Chongqing, China. Electronic address: juanjuansh@gmail.com.
  • Qian C; Research Center for Precision Medicine, Chongqing Key Laboratory of Translational Research for Cancer Metastasis and Individualized Treatment, Chongqing University Cancer Hospital, Chongqing, China. Electronic address: cqian3184@yahoo.com.cn.
Cell Signal ; 108: 110722, 2023 08.
Article en En | MEDLINE | ID: mdl-37209973

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Carcinoma Hepatocelular / Neoplasias Hepáticas / Antineoplásicos Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: Cell Signal Año: 2023 Tipo del documento: Article País de afiliación: China

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Carcinoma Hepatocelular / Neoplasias Hepáticas / Antineoplásicos Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: Cell Signal Año: 2023 Tipo del documento: Article País de afiliación: China